Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Aldeyra Therapeutics (ALDX) PT Raised to $35 at Cantor Fitzgerald Following First Successful Pivotal Trial
-
UPDATE: Cantor Fitzgerald Starts Inovio Pharmaceuticals (INO) at Overweight
-
After-Hours Movers 03/25: (LIFE) (INO) Higher; (MYOK) (ZOM) (more...)
-
Proteostasis Therapeutics (PTI) PT Lowered to $14 at Cantor Fitzgerald, Maintains 'Overweight'
-
Cantor Fitzgerald Reiterates Overweight Rating on Dermira (DERM)
-
Cohen & Company and Insurance Acquisition Corp. Announce Completion of Insurance Acquisition Corp. $150,650,000 Initial Public Offering, Including Full Exercise of Over-Allotment Option
-
Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
SELLAS Life Sciences Reports 2018 Financial Results and Provides Business Update
-
UPDATE: Aptinyx (APTX) PT Lowered to $12 at Cantor
-
U.S. Treasuries signal trouble, stocks fall on global growth worries
-
Freddie Mac Prices $908 Million Multifamily K-Deal, K-F60
-
UPDATE: Cantor Fitzgerald Downgrades Biogen (BIIB) to Neutral
-
Cellular Biomedicine Group (CBMG) Prices 1.03M Share Common Stock Offering at $17/Each
-
Cellular Biomedicine Group Announces Pricing of Public Offering of Common Stock
-
Cellular Biomedicine Group (CBMG) Announces Proposed Follow-On Common Offering
-
Cellular Biomedicine Group Announces Proposed Follow-on Offering of Common Stock
-
Cantor Fitzgerald Says New Claims About Health Insurance Innovations (HIIQ) 'Unfounded'
-
Aurinia Pharmaceuticals (AUPH) PT Raised To $24 At Cantor On Voclosporin Notice Of Allowance
-
Insurance Acquisition Corp. (INSU) Prices 13.1M Unit IPO at $10/Unit
-
Dermira (DERM) Prices 9.81M Shares Common Offering at $13.25/Sh
-
Dermira Prices $130.0 Million Public Offering of Common Stock
-
Insurance Acquisition Corp. Announces Pricing of $131,000,000 Initial Public Offering
-
Trine Acquisition Corp. Announces Closing of $261 Million Initial Public Offering
-
Trine Acquisition Corp. Announces Closing of $261 Million Initial Public Offering
-
Haymaker Acquisition Corp. Completes Business Combination with OneSpaWorld
-
Haymaker Acquisition Corp. Completes Business Combination with OneSpaWorld
-
Abeona Therapeutics (ABEO) PT Lowered to $29 at Cantor Fitzgerald; Maintains Buy
-
Amicus Therapeutics (FOLD) KOL Call Hints At Bigger Than Expected For Galafold - Cantor
-
Puma Biotechnology (PBYI) Neratinib Phase II Results Increases The Likelihood Of Commercial Contribution - Cantor
-
HealthEquity, Inc (HQY) PT Raised to $90 at Cantor Fitzgerald
-
Dermira (DERM) Plans Public Offering of Common Stock
-
Dermira Announces Proposed Public Offering of Common Stock
-
Evolus Secures $100 Million Senior Debt Facility with Oxford Finance LLC
-
Aerpio Pharmaceuticals (ARPO) PT Lowered to $3 at Cantor Fitzgerald
-
Orosur Mining Inc. – Death of Non-Executive Chairman
-
Amarin Corporation (AMRN) ACC Presentation Supports Economic Value For Vascepa - Cantor
-
Northern Dynasty Announces Closing Of US$11.5 Million Bought Deal
-
Cantor Fitzgerald Reiterates Overweight Rating on PolarityTE (PTE) Ahead Of 2 Potential Catalysts
-
Howard M. Green Joins GAMCO Investors
-
Cantor Fitzgerald to expand prime brokerage in Europe: sources
-
Freddie Mac Prices $1.4 Billion Multifamily K-Deal, K-089
-
Ra Medical Systems Inc. (RMED) PT Lowered to $11 at Cantor Fitzgerald
-
Trine Acquisition Corp. (TRNE) Prices 26.1M Unit IPO at $10/Unit
-
Trine Acquisition Corp. Announces Pricing of $261 Million Initial Public Offering
-
Trine Acquisition Corp. Announces Pricing of $261 Million Initial Public Offering
-
Cantor Fitzgerald Reiterates Overweight Rating on PolarityTE (PTE) Amid Published Case Study
-
Correvio Pharma (CORV) Reports at the Market Offering Up to $50M
-
Correvio Announces at the Market Offering
-
AMAG Pharmaceuticals (AMAG) PT Lowered to $14 at Cantor Fitzgerald
-
Orchid Island Capital Announces March 2019 Monthly Dividend and February 28, 2019 RMBS Portfolio Characteristics

